NeXtGen Biologics Successfully Completes First FDA Audit with Zero 483 Observations
GAINESVILLE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) — NeXtGen Biologics announced today the successful completion of a two-day inspection by the U.S. Food and Drug Administration (FDA). The inspection concluded with no Form 483 observations issued, underscoring the company's commitment to quality, compliance, and operational excellence. “Our vision has always been to pair scientific innovation […]